ClinicalTrials.gg
CompletedNCT07050368Updated Feb 13, 2026

A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers

A Phase 1 interventional study of Psilocybin and Placebo in Healthy Volunteer, sponsored by MycoMedica Life Sciences PBC. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by MycoMedica Life Sciences PBC · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

MLS101 is being developed as a low dose psilocybin, that can be administered to treat neurological and psychiatric conditions.

The purpose of this trial is to investigate brain activity, safety, tolerability, and PK of multiple doses of MLS101 in healthy participants.

Read the detailed description

In recent years, high-dose psilocybin has gained attention for it potential therapeutic benefit in many psychiatric conditions, however existing clinical data for low psilocybin doses are limited.

The multiple-dose regimen proposed in this study is designed to optimize the pharmacology of MLS101 and elucidate whether it provides a longer period of positive effects, which could be used in future studies in chronic indications such as PMDD, obsessive compulsive disorder and opioid use disorder. Translational functional magnetic resonance imaging (fMRI) imaging will confirm the central nervous system (CNS) activity of priming and repeat low-dose psilocybin, which will serve as a computational evaluation of efficacy and complement the cognitive and perceptual scales and questionnaires.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

MycoMedica Life Sciences PBC is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females aged 18 to 55 years old (inclusive) at the time of signing the form.
  • Standard measures are required for this clinical trial.
  • Healthy, in the opinion of the Investigator, based on prior (history of) or current (ongoing) medical and psychiatric screening assessments.
  • Participants with no findings on physical examination, laboratory tests, and cardiac assessment.
  • (BMI) within the range 18-32 kg/m2, inclusive.
  • Normal blood pressure.
  • Willing to not operate heavy machinery, including driving a vehicle at least 36 hours post Day 1 dose administration and 24 hours post all other dose administrations.
  • Capable of giving signed informed consent which includes the requirements and restrictions as per the approved study protocol

Exclusion criteria

Exclusion Criteria:

  • Prior known exposure to psilocybin, LSD, ayahuasca, N, N-Dimethyltryptamine, and related tryptamines, within the past 5 years.
  • Prior (history of) or current (ongoing) diagnosis, or first-degree relatives with medical or psychiatric condition or disease.
  • History of non-hospitalized but medicated Major Depressive Disorder (MDD), Generalized Anxiety Disorder or Panic Disorder ≤ 5 years prior to Screening.
  • History of or presence of cardiovascular disease.
  • Abnormal and clinically significant .
  • Known personal or family history of congenital long syndrome or sudden death.
  • Current or a history of orthostatic hypotension or postural orthostatic tachycardic syndrome, multiple syncopes, or unresolved/ongoing clinically significant hypotensive episodes or symptoms of fainting, dizziness, or light-headedness.
  • History or presence of a neurodegenerative disorder such Alzheimer's disease or Parkinson's disease or other behavioral disturbances resulting from other neurological disorders.
  • Use of medications that have CNS effects or affect performance.
  • Use of medications with serotonergic activity.
  • History or presence of or idiosyncratic reaction to psilocybin or related compounds or microcrystalline cellulose
  • History of substance or alcohol abuse disorder in the last 10 years.
  • Participant who, for any reason, is deemed by the Investigator to be inappropriate for this study.
  • to magnetic resonance imaging (MRI) or fMRI.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    MLS101

    Drug: Psilocybin

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Capsule containing active ingredient, psilocybin

  • DrugPlacebo

    Capsule with no active ingredients

06

What researchers measure

Primary outcomes

  1. Functional magnetic resonance imaging (fMRI).

    Global functional connectivity

    Time frame: Screening to Day 23

  2. Number and severity of treatment-emergent adverse events (TEAEs)

    An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE will be considered treatment-emergent adverse event (TEAE) if the onset date and time is at the time of or after first study drug administration.

    Time frame: Screening (Day -90) to end of study visit (Day 44)

Secondary outcomes

  1. Pharmacokinetics of MLS101: area under the plasma concentration-time curve (AUC)

    Blood sample collections

    Time frame: Day 1 to Day 16

  2. Pharmacokinetics of MLS101: maximum observed serum concentration (Cmax)

    Blood sample collections

    Time frame: Day 1 to Day 16

  3. Pharmacokinetics of MLS101: apparent terminal elimination half-life (t½)

    Blood sample collections

    Time frame: Day 1 to Day 16

  4. Pharmacokinetics of MLS101: time corresponding to the occurrence of Cmax (Tmax)

    Blood sample collection

    Time frame: Day 1 to Day 16

  5. Pharmacokinetics of MLS101: apparent total systemic clearance after oral administration (CL/F)

    Blood sample collections

    Time frame: Day 1 to Day 16

  6. Pharmacokinetics of MLS101: apparent volume of distribution during the terminal phase (Vz/F)

    Blood sample collections

    Time frame: Day 1 to Day 16

Other outcomes

  1. Perceptual effects of MLS101 using Mystical Experience Questionnaire (MEQ30) score and change from baseline score.

    The MEQ30 consists of 30 questions with each one answered from 0 (none, not at all) to 5 (extreme \[more than any other time in my life and stronger than 4\]). Full Scale ranges from 0 to 150, with higher scores indicating more psychedelic experience.

    Time frame: Day 1 to Day 16

  2. Perceptual effects of MLS101 using 5-Dimensional Altered States of Consciousness Rating Scale (5D-ASC) score and change from baseline score.

    The 5D-ASC measures altered states of consciousness and contains 94 items using visual analogue scales. Score for each will be calculated from 0 to 100 based on measurement of where the participant has selected on the line. Higher scores mean more altered state of consciousness.

    Time frame: Day 1 to Day 16

  3. Perceptual effects of MLS101 using the Acute Subjective Effects Scale (ASES) score and change from baseline score.

    The Acute Subjective Effects Scale (ASES) is a single question visual analogue scale (VAS) evaluating the present-state intensity of the psychedelic experience on a scale of 0 to 10, where 0 is 'none at all' and 10 is 'most intense'.

    Time frame: Day 1 to Day 16

  4. Cognitive function: Digit Symbol Substitution Test (DSST)

    The test taker's score is the number of correct symbol-to-number matches they complete within the allotted time. Lower score means worse outcome.

    Time frame: Day - 1 to Day 16

  5. Cognitive function: Trail Making Test A (TMT-A)

    The participant draws lines to connect circled numbers in an ascending pattern (i.e., in numerical sequence 1-2-3, etc.) as rapidly as possible. The score is the time it takes the participant to complete the task in seconds. Higher score means worse outcome.

    Time frame: Day -1 to Day 16

07

Study locations

1 site
  • Hammersmith Medicines Research (HMR)
    London, NW10 7EW, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in Jan 2026, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2025
First posted
Jul 3, 2025
StartActual
Jul 28, 2025
Primary completionActual
Jan 13, 2026
CompletionActual
Jan 13, 2026
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07050368
Lead sponsor
MycoMedica Life Sciences PBC
Responsible party
Sponsor
First posted
Jul 3, 2025
Start date
Jul 28, 2025
Primary completion
Jan 13, 2026
Completion
Jan 13, 2026
Last update
Feb 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion